共 50 条
Focal Segmental Glomerulosclerosis and Recurrence in Living Donor Recipients
被引:2
|作者:
Mang, Josef
[1
,2
,3
,4
]
Hennig, Linda
[1
,2
,3
,4
]
Liefeldt, Lutz
[2
,3
,4
,5
]
Duerr, Michael
[2
,3
,4
,5
]
Lehner, Lukas J.
[2
,3
,4
,5
]
Bichmann, Anna
[2
,3
,4
,6
]
Ralla, Bernhard
[1
,2
,3
,4
]
Cash, Hannes
[7
]
Kanne, Martin Christopher
[8
]
Peters, Robert
[1
,2
,3
,4
]
Maxeiner, Andreas
[1
,2
,3
,4
]
Friedersdorff, Frank
[1
,2
,3
,4
,8
]
机构:
[1] Charite Univ Med Berlin, Dept Urol, Charitepl 1, D-10117 Berlin, Germany
[2] Free Univ Berlin, Charitepl 1, D-10117 Berlin, Germany
[3] Humboldt Univ, Charitepl 1, D-10117 Berlin, Germany
[4] Berlin Inst Hlth, Charitepl 1, D-10117 Berlin, Germany
[5] Charite Univ Med Berlin, Dept Nephrol, Berlin, Germany
[6] Charite Univ Med Berlin, Dept Anesthesiol & Operat Intens Care Med, Campus Charite Mitte, Berlin, Germany
[7] PROURO, Berlin, Germany
[8] Evangel Krankenhaus Konigin Elisabeth Herzberge, Dept Urol, Berlin, Germany
来源:
RESEARCH AND REPORTS IN UROLOGY
|
2021年
/
13卷
关键词:
FSGS;
living donor nephrectomy;
recurrence;
KIDNEY-TRANSPLANT RECIPIENTS;
OUTCOMES;
D O I:
10.2147/RRU.S308994
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Purpose: Focal segmental glomerulosclerosis (FSGS) is a common cause for end-stage renal disease that can recur in the graft after kidney transplantation. The incidence of FSGS recurrence is reported in up to 47% of patients, predisposing those to possible poorer transplantation outcomes. Hence, we examined the incidence of FSGS recurrence and the effect on graft outcome in our patient cohort of living donor kidney transplantations (LDKT). Patients and Methods: We analyzed 194 adult patients who received a LDKT between 2011 and 2017 of which 22 (11%) had FSGS as underlying disease. Demographic data and clinical outcomes, especially regarding recurrence of FSGS, were evaluated. Results: FSGS recurrence was identified in three (14%) patients within three months after transplantation, of whom two patients (9%) lost their graft. There was no significant difference in graft survival comparing FSGS to other reasons for end-stage renal disease. Conclusion: Incidence of FSGS recurrence in the present patient cohort was within the range reported in the literature and comparatively low. Our data support LDKT as a treatment option in patients with end-stage renal disease due to FSGS.
引用
收藏
页码:495 / 499
页数:5
相关论文